Friday, July 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 4 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 11718679

    CD137 antibodies and PD-1 antagonists and uses thereof

    Compass Therapeutics LLC · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted

  2. US 11713324

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted

  3. US 11707506

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted

  4. US 11690825

    20-HETE receptor (GPR75) antagonists and methods of use

    The Board of Regents of the University of Texas System · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted

  5. US 11666547

    Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1)

    Northwestern University · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted

  6. US 11603408

    Methods for treating skin infection by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted

  7. US 11597707

    CGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted

  8. US 11590135

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  9. US 11584736

    Heterocyclic P2Y14 receptor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted

  10. US 11571412

    Thromboxane receptor antagonists in AERD/asthma

    Cumberland Pharmaceuticals Inc. · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted

  11. US 11566015

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted

  12. US 11559564

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted

  13. US 11548887

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted

  14. US 11548890

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted

  15. US 11504426

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  16. US 11505585

    FcRn antagonists and methods of use

    The Board of Regents of the University of Texas System · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  17. US 11472772

    S1P3 antagonists

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted

  18. US 11466010

    Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  19. US 11464830

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  20. US 11452723

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Theravance Biopharma R&D IP, LLC · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted

  21. US 11434268

    Vascular endothelial growth factor antagonists

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  22. CA 3202908

    ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE

    ADVANCED ACCELERATOR APPLICATIONS INT SA [CH] · Granted Jun 30, 2022 · Expires Jun 25, 2042

    granted

  23. US 11351177

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted

  24. US 11344557

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.